Pharma Sector Sees Flurry of Deals
A series of key pharmaceutical developments were recently highlighted, signaling continued activity in the sector. The updates include a label expansion for CStone’s sugemalimab in the UK, a new exclusive license between HBM Holdings and Solstice Oncology, and progress on a prostate cancer drug from Astellas and Vir.
The Astellas and Vir Biotechnology collaboration on prostate cancer therapy VIR-5500 involves significant financial commitments, with Vir set to receive $335 million in upfront and near-term payments. The agreement also makes Vir eligible for up to $1.37 billion in future milestones, plus tiered, double-digit royalties on sales outside the U.S. Under the terms of the deal, Astellas will lead commercialization in the United States, though Vir retains an option to co-promote. Astellas will hold exclusive commercial rights outside the U.S., and the two companies will share global development costs, with Astellas covering 60% and Vir handling 40%. The exclusive license between HBM Holdings and Solstice Oncology centers on HBM4003, a next-generation anti-CTLA-4 antibody. For granting ex-China rights to Solstice, HBM is eligible for over $105 million in upfront consideration—including $50 million in cash and over $50 million in equity—and up to $1.1 billion in milestone payments. CStone’s sugemalimab approval in the UK is for unresectable, stage III non-small cell lung cancer, its second indication for the drug in the country. The approval from the Medicines and Healthcare products Regulatory Agency (MHRA) was based on the GEMSTONE-301 Phase III study, which showed a statistically significant improvement in progression-free survival. These transactions reflect a broader trend in the pharmaceutical industry, which has seen a rebound in the value of mergers and acquisitions. Oncology remains a primary focus for M&A deal value, alongside immunology. For Woonsocket, home to the headquarters of CVS Health, this sector activity is part of a larger economic picture. Neighboring Massachusetts is a major hub for the pharmaceutical industry, and Rhode Island itself is home to over 400 life sciences companies and is actively investing to grow its presence in the rapidly expanding global biotech market.
